114 related articles for article (PubMed ID: 2390716)
21. Effect of systemic glutathione depletion by buthionine sulfoximine on sensitivity of murine bladder cancer to cytotoxic agents.
Lee KE; Mayer RD; Cockett AT
Urology; 1989 Dec; 34(6):376-80. PubMed ID: 2595883
[TBL] [Abstract][Full Text] [Related]
22. Injurious effect of buthionine sulfoximine, an inhibitor of glutathione biosynthesis, on the lethality and urotoxicity of cyclophosphamide in mice.
Ishikawa M; Sasaki K; Takayanagi Y
Jpn J Pharmacol; 1989 Sep; 51(1):146-9. PubMed ID: 2810938
[TBL] [Abstract][Full Text] [Related]
23. Enhancement of murine phenytoin teratogenicity by the gamma-glutamylcysteine synthetase inhibitor L-buthionine-(S,R)-sulfoximine and by the glutathione depletor diethyl maleate.
Wong M; Helston LM; Wells PG
Teratology; 1989 Aug; 40(2):127-41. PubMed ID: 2772848
[TBL] [Abstract][Full Text] [Related]
24. Effect of depletion of glutathione by buthionine sulfoximine on lipid peroxidation in rats acutely treated with ethanol.
Koçak-Toker N; Mutlu-Türkoğlu U; Alptekin N; Uysal M
Int J Biochem; 1993 Dec; 25(12):1765-8. PubMed ID: 8138014
[TBL] [Abstract][Full Text] [Related]
25. Toxic effects of acute glutathione depletion by buthionine sulfoximine and dimethylfumarate on murine mammary carcinoma cells.
Dethlefsen LA; Lehman CM; Biaglow JE; Peck VM
Radiat Res; 1988 May; 114(2):215-24. PubMed ID: 3375425
[TBL] [Abstract][Full Text] [Related]
26. Buthionine sulfoximine protects the viability of adult rat Leydig cells exposed to ethane dimethanesulfonate.
Kelce WR
Toxicol Appl Pharmacol; 1994 Apr; 125(2):237-46. PubMed ID: 8171431
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of glutathione synthesis as a chemotherapeutic strategy for trypanosomiasis.
Arrick BA; Griffith OW; Cerami A
J Exp Med; 1981 Mar; 153(3):720-5. PubMed ID: 7252412
[TBL] [Abstract][Full Text] [Related]
28. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer.
O'Dwyer PJ; Hamilton TC; LaCreta FP; Gallo JM; Kilpatrick D; Halbherr T; Brennan J; Bookman MA; Hoffman J; Young RC; Comis RL; Ozols RF
J Clin Oncol; 1996 Jan; 14(1):249-56. PubMed ID: 8558205
[TBL] [Abstract][Full Text] [Related]
29. Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione.
Bailey HH; Mulcahy RT; Tutsch KD; Arzoomanian RZ; Alberti D; Tombes MB; Wilding G; Pomplun M; Spriggs DR
J Clin Oncol; 1994 Jan; 12(1):194-205. PubMed ID: 8270977
[TBL] [Abstract][Full Text] [Related]
30. Glutathione depletion by DL-buthionine-SR-sulfoximine (BSO) potentiates X-ray-induced chromosome lesions after liquid holding recovery.
Bertsche U; Schorn H
Radiat Res; 1986 Mar; 105(3):351-69. PubMed ID: 3754339
[TBL] [Abstract][Full Text] [Related]
31. Enhancement of cisplatin toxicity by buthionine sulfoximine, a glutathione-depleting agent, in mice.
Ishikawa M; Takayanagi Y; Sasaki K
Res Commun Chem Pathol Pharmacol; 1990 Jan; 67(1):131-41. PubMed ID: 2326543
[TBL] [Abstract][Full Text] [Related]
32. Combined effects of buthionine sulfoximine and cepharanthine on cytotoxic activity of doxorubicin to multidrug-resistant cells.
Kisara S; Furusawa S; Murata R; Ogata M; Hikichi N; Takayanagi Y; Sasaki K
Oncol Res; 1995; 7(3-4):191-200. PubMed ID: 8555653
[TBL] [Abstract][Full Text] [Related]
33. Influence of buthionine sulfoximine and misonidazole on glutathione level and radiosensitivity of human tumor xenografts.
Guichard M; Lespinasse F; Malaise EP
Radiat Res; 1986 Jan; 105(1):115-25. PubMed ID: 3945723
[TBL] [Abstract][Full Text] [Related]
34. The pulmonary effects of buthionine sulfoximine treatment and glutathione depletion in rats.
Coursin DB; Cihla HP
Am Rev Respir Dis; 1988 Dec; 138(6):1471-9. PubMed ID: 3202501
[TBL] [Abstract][Full Text] [Related]
35. Glutathione metabolism in the lung: inhibition of its synthesis leads to lamellar body and mitochondrial defects.
Mårtensson J; Jain A; Frayer W; Meister A
Proc Natl Acad Sci U S A; 1989 Jul; 86(14):5296-300. PubMed ID: 2748585
[TBL] [Abstract][Full Text] [Related]
36. L-buthionine sulfoximine potentiates the antitumor effect of 4-hydroperoxycyclophosphamide when administered locally in a rat glioma model.
Sipos EP; Witham TF; Ratan R; Burger PC; Baraban J; Li KW; Piantadosi S; Brem H
Neurosurgery; 2001 Feb; 48(2):392-400. PubMed ID: 11220384
[TBL] [Abstract][Full Text] [Related]
37. Buthionine sulfoximine spares intracellular glutamate: a possible mechanism for cell growth stimulation.
Kang YJ
Cell Mol Biol Res; 1993; 39(7):675-84. PubMed ID: 8055000
[TBL] [Abstract][Full Text] [Related]
38. Plasma glutathione turnover in the rat: effect of fasting and buthionine sulfoximine.
Hum S; Robitaille L; Hoffer LJ
Can J Physiol Pharmacol; 1991 May; 69(5):581-7. PubMed ID: 1863907
[TBL] [Abstract][Full Text] [Related]
39. Roles of catalase and the glutathione redox cycle in the regulation of anterior-chamber hydrogen peroxide.
Costarides AP; Riley MV; Green K
Ophthalmic Res; 1991; 23(5):284-94. PubMed ID: 1784460
[TBL] [Abstract][Full Text] [Related]
40. Effect of glutathione depletion by L-buthionine sulfoximine on the cytotoxicity of cyclophosphamide in single and fractionated doses to EMT6/SF mouse tumors and bone marrow.
Ono K; Shrieve DC
J Natl Cancer Inst; 1987 Oct; 79(4):811-5. PubMed ID: 3477662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
